inclusion criteria patients ≥18 years of age hospitalized with laboratory confirmed covid-19 one or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal cxr/ct imaging) hospitalized for ≤ 72 hours or within day 3 to 7 days from first signs of illness on supplemental oxygen, non-invasive ventilation or high-flow oxygen patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis. exclusion criteria receipt of pooled immunoglobulin in past 30 days contraindication to transfusion or history of prior reactions to transfusion blood products invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) volume overload secondary to congestive heart failure or renal failure unlikely to survive past 72 hours from screening based on the assessment of the investigator unlikely to be able to assess and follow outcome due to poor functional status

inclusion criteria patients ≥18 years of age hospitalized with laboratory confirmed covid-19 one or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal cxr/ct imaging) hospitalized for ≤ 72 hours or within day 3 to 7 days from first signs of illness on supplemental oxygen, non-invasive ventilation or high-flow oxygen patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis. exclusion criteria receipt of pooled immunoglobulin in past 30 days contraindication to transfusion or history of prior reactions to transfusion blood products invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) volume overload secondary to congestive heart failure or renal failure unlikely to survive past 72 hours from screening based on the assessment of the investigator unlikely to be able to assess and follow outcome due to poor functional status

inclusion criteria 1. patients ≥18 years of age 2. hospitalized with laboratory confirmed covid-19 3. one or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal cxr/ct imaging) 4. hospitalized for ≤ 72 hours or within day 3 to 7 days from first signs of illness 5. on supplemental oxygen, non-invasive ventilation or high-flow oxygen 6. patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis. exclusion criteria 1. receipt of pooled immunoglobulin in past 30 days 2. contraindication to transfusion or history of prior reactions to transfusion blood products 3. invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 4. volume overload secondary to congestive heart failure or renal failure 5. unlikely to survive past 72 hours from screening based on the assessment of the investigator 6. unlikely to be able to assess and follow outcome due to poor functional status

inclusion criteria 1. patients ≥18 years of age 2. hospitalized with laboratory confirmed covid-19 3. one or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal cxr/ct imaging) 4. hospitalized for ≤ 72 hours or within day 3 to 7 days from first signs of illness 5. on supplemental oxygen, non-invasive ventilation or high-flow oxygen 6. patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis. exclusion criteria 1. receipt of pooled immunoglobulin in past 30 days 2. contraindication to transfusion or history of prior reactions to transfusion blood products 3. invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 4. volume overload secondary to congestive heart failure or renal failure 5. unlikely to survive past 72 hours from screening based on the assessment of the investigator 6. unlikely to be able to assess and follow outcome due to poor functional status